Live Virtual Symposium: Right Patient, Right Treatment, Right Time: Utilizing Early, High-Efficacy Therapies to Improve Outcomes in RRMS

Live Virtual Symposium: Right Patient, Right Treatment, Right Time: Utilizing Early, High-Efficacy Therapies to Improve Outcomes in RRMS is organized by CME Outfitters, LLC.

Symposium Date/Time: Thursday, June 4, 2020 | 6:30 PM - 8:00 PM ET
Credit Expiration Date: Friday, June 4, 2021

Target Audience:
Neurologists, MS specialists, PAs, nurse practitioners, nurses, and pharmacists

This activity offers CE credit for:
•  Physicians (CME)
•  Nurses (CNE)
•  Pharmacists (ACPE)
•  ABIM (MOC)
•  Other

All other clinicians will gain a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™.

Credit Information
CME Credit (Physicians):
CME Outfitters, LLC, is authorized by the Accreditation Council for Continuing Medical Education (ACCME) to present continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will admit AMA PRA Category 1 Credit™ from organizations authorized by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hour (0.15 CEUs). Universal Activity Number:

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Statement of Need
Recent studies have demonstrated the benefits of early and aggressive treatment strategies in reducing disability progression and the frequency of relapses in patients with relapsing remitting multiple sclerosis (RRMS), marking a paradigm shift in the treatment of patients with RRMS. The traditional escalation approach is now often set aside in favor of the more individualized "induction" approach, which utilizes "early and aggressive" treatment with high-efficacy disease-modifying therapies (DMTs) to treat patients with high-risk disease.

The induction approach requires selection of DMTs based on disease activity, prognostic factors, and patient characteristics. This is challenging for clinicians due to the expanding treatment landscape for RRMS and the lack of specific guidelines. Additionally, neurologists often lack the knowledge and competence to identify patients who are candidates for this approach.

In this CME Outfitters live virtual symposium, expert faculty will focus on the prognostic factors that should be considered when developing treatment plans for patients with MS, as well as the latest clinical data on approved and emerging DMTs, so that clinicians can confidently develop tailored treatment approaches based on individual patient characteristics and appropriately monitor treatment response, safety, and tolerability.

Learning Objectives
At the conclusion of this CE activity, participants should be able to:
•  Preferred patients with RRMS who are likely to benefit from early treatment with high-efficacy DMTs.
•  Generate tailored treatment methods based on individual patient characteristics.
•  Employ the latest clinical data on approved and emerging DMTs in monitoring treatment response, safety, and tolerability.

The following learning objectives pertain only to those requesting CNE or CPE credit:
•  Define patients with RRMS who are likely to benefit from early treatment with high-efficacy DMTs.
•  Review tailored treatment approaches based on individual patient characteristics.
•  Describe the latest clinical data on recognized and emerging DMTs in monitoring treatment response, safety, and tolerability.